tbuckley/cabot-search huggingface dataset:
LG-50MULTIPLEX DETECTION OF PEDIATRIC LOW GRADE GLIOMA SIGNATURE FUSION AND DUPLICATION TRANSCRIPTS USING THE NANOSTRING NCOUNTER SYSTEM
Authors: Scott Ryall, Anthony Arnoldo, Rahul Krishnatry, Kangzi Khor, Matthew Mistry, Uri Tabori, Cynthia Hawkins
Journal: Neuro-Oncology (2016)
Margaret McCartney: Misinformation in the EU debate
Authors: Margaret McCartney
Journal: BMJ (2016)

I like facts, and I love evidence—bring it on. “Official information about the referendum,” says one leaflet, pushed through the door because I’m “someone who cares about the future of Scotland and fair access to public services.”

A sum equivalent to building a new hospital, £350m (€442m; $496m), is spent each week on our EU membership. Five new countries are “in the queue” to join the European Union, and I have to decide “whether this will help Scotland . . . and fair access to public services.” It has graphs of increasing “billions sent to the …
RO-06INCIDENCE OF CATARACT DEVELOPMENT IN PEDIATRIC PATIENTS RECEIVING CRANIOSPINAL IRRADIATION
Authors: Ros Whelan, Todd Hankinson, Kathleen Dorris, Benjamin Saccomano, Michael Handler, Arthur Liu, Molly Hemenway, Jennifer Madden
Journal: Neuro-Oncology (2016)

RO-06. INCIDENCE OF CATARACT DEVELOPMENT IN PEDIATRIC PATIENTS RECEIVING CRANIOSPINAL IRRADIATION Ros Whelan, Todd Hankinson, Kathleen Dorris, Benjamin Saccomano, Michael Handler, Arthur Liu, Molly Hemenway, and Jennifer Madden; Children’s Hospital Colorado, Aurora, CO, USA OBJECTIVE: Craniospinal irradiation (CSI) is an important component of therapy for some children with brain tumors. CSI has been associated with numerous late effects, but there is a paucity of data regarding cataract development following CSI. We investigated the incidence of cataracts in children treated at our institution. METHODS: Single center retrospective analysis of children with primary intracranial neoplasms who received CSI between 07/2007 and 06/2015. Data included tumor histologyand location, radiation dose, cataract development and intervention. RESULTS: Sixty-five children received CSI over that time period (57 embryonal tumors, 5 germ cell tumors, 3 pineal tumors) and 46 had eye exams. Median CSI dose was 23.4 Gy (range 12 36 Gy). With a median follow up of 25.0 months, thirteen (28%) developed cataracts with a median time to develop cataracts of 27.6 months (range 20-60 months). Six have required intervention. CONCLUSIONS: Development of cataracts is a significant risk in children who require CSI for the treatment of a brain tumor. Routine eye exams should be included with long term follow-up. Further study will better delineate risk factors for the development of cataracts, allowing appropriate screening and management for these patients. Neuro-Oncology 18:iii159–iii164, 2016. doi:10.1093/neuonc/now082.6 #The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
The endothelial adrenomedullin-RAMP2 system regulates vascular integrity and suppresses tumour metastasis
Authors: Megumu Tanaka, Teruhide Koyama, Takayuki Sakurai, Akiko Kamiyoshi, Yuka Ichikawa-Shindo, Hisaka Kawate, Tian Liu, Xian Xian, Akira Imai, Liuyu Zhai, Kazutaka Hirabayashi, Shinji Owa, Akihiro Yamauchi, Kyoko Igarashi, Shun'ichiro Taniguchi, Takayuki Shindo
Journal: Cardiovascular Research (2016)

Aims Controlling vascular integrity is expected to be a novel therapeutic target of cancers as well as cardiovascular diseases. Adrenomedullin (AM) and its receptor-modulating protein, RAMP2, have been identified as essential mediators of cardiovascular homeostasis. In this study, we used inducible vascular endothelial cell-specific RAMP2 knockout (DI-E-RAMP2−/−) mice to clarify the contribution made by the endogenous AM-RAMP2 system to angiogenesis and metastasis. Methods and results Subcutaneously transplanted sarcoma or melanoma cells showed less growth and angiogenesis in DI-E-RAMP2−/− than in control mice. On the other hand, after the transplantation of B16BL6 melanoma cells into hindlimb footpads, spontaneous metastasis to the lung was enhanced in DI-E-RAMP2−/− mice. Early after RAMP2 gene deletion, DI-E-RAMP2−/− mice showed enhanced vascular permeability, endothelial–mesenchymal transition (EndMT)-like change, and systemic oedema. Within the lungs of DI-E-RAMP2−/− mice, pulmonary endothelial cells were deformed, and inflammatory cells infiltrated the vessel walls and expressed the chemotactic factors S100A8/9 and SAA3, which attract tumour cells and mediate the formation of a pre-metastatic niche. Conversely, the overexpression of RAMP2 suppressed tumour cell adhesion to endothelial cells, tumour metastasis, and improved survival. Conclusion These findings indicate that the AM-RAMP2 system regulates vascular integrity, whereas RAMP2 deletion promotes vascular permeability and EndMT-like change within primary lesions and formation of pre-metastatic niches in distant organs by destabilizing the vascular structure and inducing inflammation. Vascular integrity regulated by the AM-RAMP2 system could thus be a hopeful therapeutic target for suppressing tumour metastasis.
Effect of Sodium–Glucose Cotransporter 2 Inhibitors on Diabetic Ketoacidosis Among Patients With Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials
Authors: Huilin Tang, Dandan Li, Tiansheng Wang, Suodi Zhai, Yiqing Song
Journal: Diabetes Care (2016)

Sodium–glucose cotransporter 2 (SGLT2) inhibitors are a novel class of antidiabetes drugs for the treatment of type 2 diabetes (T2D) (1). In addition to their hypoglycemic effect, SGLT2 inhibitors also offer several beneficial effects, such as weight loss and blood pressure reduction (1). However, the overall health benefits of these drugs needed to outweigh their possible side effects. Recently, cumulative evidence suggests that SGLT2 inhibitors may lead to diabetic ketoacidosis (DKA), which is a serious acute complication of diabetes (2,3). In May 2015, the U.S. Food and Drug Administration issued an updated drug safety communication warning about SGLT2 inhibitors potentially increasing the risk of DKA (4). As DKA is a rare adverse effect, the evidence from individual studies or simply pooling the numbers from multiple reports is generally weak. Therefore, we conducted a meta-analysis of randomized controlled trials (RCTs) …
HG-38INHIBITING PBX-HOX BINDING IN PAEDIATRIC GLIOMA STEM CELLS AS A NOVEL THERAPEUTIC TREATMENT IN GLIOBLASTOMA
Authors: William Rogers, Richard Morgan, Hardev Pandha
Journal: Neuro-Oncology (2016)

HG-38. INHIBITING PBX-HOX BINDING IN PAEDIATRIC GLIOMA STEM CELLS AS A NOVEL THERAPEUTIC TREATMENT IN GLIOBLASTOMA William Rogers1, Richard Morgan2, and Hardev Pandha1; University of Surrey, Guildford, Surrey, UK; University of Bradford, Bradford, West Yorkshire, UK INTRODUCTION: The HOX genes encode a familyof transcription factors that play an essential role in embryonic patterning, but are dysregulated in numerous cancers, including glioblastoma. Previous research indicates that all HOX genes are expressed at varying levels in glioblastoma cells, but are highly expressed in glioma stem cells. Previously we reported that disrupting HOX-PBX binding using the HXR9 peptide induced adult glioblastoma cell lines to undergo apoptosis, and that glioma stem cells were the most sensitive to HXR9-mediated killing. In this study we assessed whether HXR9 could also kill paediatric glioma stem cells. METHODS: HOX and PBX expression was determined using quantitative RT-PCR. Glioma cell lines were enriched for glioma stem cells and evaluated for the presence of stem cell markers. Glioma and glioma stem cells were then treated with HXR9, and cell viability was determined by MTS assay. RESULTS: Glioma cell lines showed elevated HOX and PBX expression compared to normal astrocytes, with glioma stem cells exhibiting the highest expression levels. HXR9 showed dose dependent cytotoxicity in all cell lines, and glioma stem cells were the most sensitive. CONCLUSION: Initial results show that HOX and PBX genes are aberrantly expressed in paediatric glioma cells, with glioma stem cells showing the highest expression levels. HXR9 is cytotoxic against glioma cells and glioma stem cells. FUTURE WORK: To assess the expression levels of HOX and PBX genes in normal paediatric brains, to study the mechanism of HXR9-induced cell death, and determine the downstream genes affected by HXR9 treatment. Neuro-Oncology 18:iii48–iii77, 2016. doi:10.1093/neuonc/now073.35 #The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Paper Partition Chromatography of Amino Acids of Gastric Juice of Patients with Gastric Lesions&lt;xref ref-type="author-notes" rid="fn1"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: Warren, Shields, Gilligan, D. Rourke, Moor, J. Rothwell
Journal: JNCI Journal of the National Cancer Institute (1951)

Journal Article Paper Partition Chromatography of Amino Acids of Gastric Juice of Patients with Gastric Lesions Get access Shields Warren, M. D., Shields Warren, M. D. Laboratories of Pathology of the New England Deaconess Hospital and the Harvard Cancer Commission, Boston, Mass. Search for other works by this author on: Oxford Academic PubMed Google Scholar D. Rourke Gilligan, M. S., D. Rourke Gilligan, M. S. Laboratories of Pathology of the New England Deaconess Hospital and the Harvard Cancer Commission, Boston, Mass. Search for other works by this author on: Oxford Academic PubMed Google Scholar J. Rothwell Moor, M. S. J. Rothwell Moor, M. S. Laboratories of Pathology of the New England Deaconess Hospital and the Harvard Cancer Commission, Boston, Mass. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 12, Issue 3, December 1951, Pages 677–689, https://doi.org/10.1093/jnci/12.3.677 Published: 01 December 1951 Article history Received: 01 August 1951 Published: 01 December 1951
Boxing in the army
Authors: D H Wright
Journal: JAMA (1989)

<h3>To the Editor. —</h3> The article titled "Boxing-Related Injuries in the US Army, 1980 Through 1985"<sup>1</sup>contains important information about this cause of injury. From the information they obtained, the authors made a giant leap from being scientists to being experts in military preparedness and questioned the advisability of promoting boxing in the US Army. This was done in such a way that one can only conclude they believe it should be banned. In doing so they may have meant well but this action is misguided or naive. In matters of prevention, diagnosis, and treatment of illness and injuries, the opinions of physicians have special status. The authors seem to believe they also have special competence to judge whether boxing does more harm than good as a tool to develop soldiers. In other words, they address the broader question of the appropriateness of boxing as a military training tool.
Board certification anxiety
Authors: F G Maleson, P J Fink, H L Field
Journal: American Journal of Psychiatry (1980)

The authors discuss how stress influences the candidate's capacity to effectively prepare for and fully demonstrate his or her abilities in the oral examination in psychiatry given by the American Board of Psychiatry and Neurology. They highlight subtle misconceptions about examiner priorities, attitudes, and evaluation methods and note common errors that reflect both anxiety and these misconceptions. They offer some advice and information to aid the candidate in coping with these examination difficulties.
Abstract 4646: Visually-Guided Ablation of the Pulmonary Venous Antrum Using a Compliant Balloon Catheter
Authors: Vivek Y Reddy, Shephal K Doshi, Andre d’Avila, Petr Neuzil, Young-Hoon Kim
Journal: Circulation (2008)

Introduction: During AF ablation, placing contiguous point ablations to electrically isolate the PVs can be technically challenging. While balloon ablation catheters (BACs) using various energy sources can facilitate this procedure, they are limited by the relatively distal nature of the level of isolation; the PV antra remain largely un-ablated. This report details the in vivo evaluation of a compliant BAC with 1) the capability for endoscopic real-time visualization of the target tissue, and 2) an adjustable short arc of light energy for ablation. Methods: In 3 normal pigs, transseptal access was achieved followed by placement of a deflectable sheath and the BAC (Cardiofocus Inc). Once in position, a 30° arc of laser energy (980 nm) was manipulated to create an isolating antral lesion set. PV isolation was confirmed using a circular mapping catheter. The level of isolation was also visualized by high-density electroanatomical mapping (NavX, St Jude Medical Inc). Results: The BAC was able to conform to the PV antra (Fig-A/B ); a 3D reconstruction of the BAC while in position is shown in Fig C . Circumferential endoscopic contact was observed for all 4 PVs targeted for ablation (3-RSPVs, 1-LSPV). Electrical PV isolation was achieved for all 4 PVs. The level of RSPV (arrow) isolation is seen on the voltage maps at baseline (Fig D ), post-partial ablation (Fig E ) and post-isolation (Fig F ); shown are PA views. There was no PV stenosis, thrombus formation or atrial perforation. Pathological examination confirmed the lesions to be both transmural and antral in location. Conclusions: The PV antra can be targeted for ablation using this visually-guided compliant balloon ablation system.
Characteristics of 275 patients with bulimia
Authors: J E Mitchell, D Hatsukami, E D Eckert, R L Pyle
Journal: American Journal of Psychiatry (1985)

The authors present data on 275 patients who met DSM-III criteria for bulimia. The mean age of the patients was 24.8 years, and the average duration of illness was approximately 7 years. These patients reported a variety of abnormal eating-related behaviors: binge eating (100%), self-induced vomiting (88.1%), laxative abuse (60.6%), diuretic abuse (33.1%), and chewing and spitting out food (64.5%). Over one-third reported a history of problems with alcohol or other drugs and most indicated substantial social impairment.
MB-94IMMUNOLOGIC PROFILE OF PATIENTS WITH NEWLY-DIAGNOSED MEDULLOBLASTOMA AT INITIAL DIAGNOSIS AND DURING STANDARD RADIATION AND CHEMOTHERAPY (PBTC-N11)
Authors: Sridharan Gururangan, Elizabeth Reap, Renee Reynolds, Gerald Grant, Arzu Onar-Thomas, Mehmet Kodak, Patricia Baxter, Ian Pollack, Peter Phillips, James Boyett, Maryam Fouladi, Duane Mitchell
Journal: Neuro-Oncology (2016)
HG-80ISSUES IN THE MANAGEMENT OF CHILDREN WITH BRAIN TUMORS AND BIALLELIC MISMATCH GENE REPAIR DEFICIENCY SYNDROME
Authors: Roula Farah, Farid Maalouf, Nassim Abi-Chahine, Hussein Farhat, Brittany Campbell, Nataliya Zhukova, Carol Durno, Melyssa Aronson, Cynthia Hawkins, Eric Bouffet, Uri Tabori
Journal: Neuro-Oncology (2016)

HG-80. ISSUES IN THE MANAGEMENT OF CHILDREN WITH BRAIN TUMORS AND BIALLELIC MISMATCH GENE REPAIR DEFICIENCY SYNDROME Roula Farah1, Farid Maalouf1, Nassim Abi-Chahine1, Hussein Farhat2, Brittany Campbell3, Nataliya Zhukova3, Carol Durno3, Melyssa Aronson4, Cynthia Hawkins3, Eric Bouffet3, and Uri Tabori3; Saint George Hospital University Medical Center, Beirut, Lebanon; Lebanese American University Medical Center-Rizk Hospital, Beirut, Lebanon; The Hospital for Sick Children,Toronto,ON,Canada;MountSinaiHospital,Toronto,ON,Canada Biallelic mismatch repair deficiency (bMMRD) is a rare cancer predisposition syndrome, presenting in childhood. Affected patients have cafe-au-lait skin lesions and develop various hematological, gastrointestinal and CNS malignancies. Although guidelines are available for surveillance, there is scarce information about optimal therapy. We report the pedigree, diagnostic studies and clinical course of a consanguinous family with four children, the index case, his sister and two first cousins, affected by the syndrome. The index case developed glioblastoma and T-cell leukemia and died from infection while in complete remission. His sister is under treatment for a high-grade glioma, and his two first-cousins died of their brain cancer. DNA from peripheral blood, saliva and buccal swabs, skin biopsies and paraffin blocks from tumor tissue were used for genetic testing. Both tumor and normal tissue were stained for the presence of the MMR proteins through immunohistochemistry and revealed absence of the PMS2 protein in both tissues. Molecular analysis was performed using Sanger sequencing and MLPA of the 4 MMR genes. A pathogenic, heterozygous mutation was identified in the PMS2 gene (exon15del c.2446-?_2589 + ?del) in the affected children and their fathers. Review of the clinical course of the index case revealed increased morbidity and toxicity compared to other children undergoing therapy on the same protocol. We suggest more adapted treatment protocols for these patients. This family illustrates difficulties encountered in the diagnosis, surveillance and choice of therapy for children affected with bMMRD and the need for increased awareness and more information about this rare but important syndrome. Neuro-Oncology 18:iii48–iii77, 2016. doi:10.1093/neuonc/now073.76 #The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Calculating
Authors: M Therese Southgate
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Virus of Avian Erythroblastosis. VII. Ultra-structure of Erythroblasts From the Chicken and From Tissue Culture&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Heine, Ursula, Beaudreau, G. S., Becker, Caroline, Beard, Dorothy, Beard, J. W.
Journal: JNCI Journal of the National Cancer Institute (1961)

Journal Article Virus of Avian Erythroblastosis. VII. Ultra-structure of Erythroblasts From the Chicken and From Tissue Culture Get access Ursula Heine, Ursula Heine Department of Surgery, Duke University Medical Center, Durham, North Carolina Search for other works by this author on: Oxford Academic PubMed Google Scholar G. S. Beaudreau, G. S. Beaudreau Department of Surgery, Duke University Medical Center, Durham, North Carolina Search for other works by this author on: Oxford Academic PubMed Google Scholar Caroline Becker, Caroline Becker Department of Surgery, Duke University Medical Center, Durham, North Carolina Search for other works by this author on: Oxford Academic PubMed Google Scholar Dorothy Beard, Dorothy Beard Department of Surgery, Duke University Medical Center, Durham, North Carolina Search for other works by this author on: Oxford Academic PubMed Google Scholar J. W. Beard J. W. Beard Department of Surgery, Duke University Medical Center, Durham, North Carolina Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 26, Issue 2, February 1961, Pages 359–388, https://doi.org/10.1093/jnci/26.2.359 Published: 01 February 1961 Article history Received: 08 August 1960 Published: 01 February 1961
Transdermal Buprenorphine Relieves Neuropathic Pain: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial in Diabetic Peripheral Neuropathic Pain
Authors: Richard W. Simpson, John H. Wlodarczyk
Journal: Diabetes Care (2016)

OBJECTIVE To evaluate the efficacy and safety of transdermal buprenorphine in patients with diabetic peripheral neuropathic pain (DPNP). RESEARCH DESIGN AND METHODS This multicenter, randomized, double-blind, placebo-controlled, parallel-group trial enrolled patients with type 1 or type 2 diabetes and stable glycemic control who had been experiencing moderate to severe DPNP for at least 6 months on maximal tolerated conventional therapy. Patients were randomly assigned to receive buprenorphine (5 μg/h) or placebo patches. The dose was titrated to effect to a maximum of 40 μg/h. Paracetamol was available as rescue analgesia. The severity of pain and other symptoms of DPNP were assessed daily in a patient diary and at clinic visits. RESULTS One hundred eight-six patients were enrolled, with 93 randomized to either buprenorphine or placebo. A high proportion of patients did not complete the study (buprenorphine 37 of 93, placebo 24 of 93). The main reason for premature withdrawal in the buprenorphine group was adverse events commonly due to untreated nausea and/or vomiting. Among the per-protocol population, more patients in the buprenorphine group (86.3%) experienced a 30% reduction in average versus baseline pain at week 12 than those in the placebo group (56.6%, P &amp;lt; 0.001). A nonsignificant trend favored the buprenorphine group within the intention-to-treat analysis of the same end point (51.7% vs. 41.3%, P = 0.175). CONCLUSIONS Transdermal buprenorphine, when tolerated, is an effective therapy for DPNP and provides another option to manage this challenging painful condition. Nausea and constipation need to be managed proactively to optimize treatment outcomes.
Lung Cancer Screening: Recommendation Statement
Journal: Annals of Internal Medicine (2004)

This statement summarizes the current U.S. Preventive Services Task Force (USPSTF) recommendation on screening for lung cancer and the supporting scientific evidence and updates the 1996 recommendations on this topic. In 1996, the USPSTF recommended against screening for lung cancer (a grade D recommendation). The Task Force now uses an explicit process in which the balance of benefits and harms is determined exclusively by the quality and magnitude of the evidence. As a result, current letter grades are based on different criteria than those used in 1996. The complete information on which this statement is based, including evidence tables and references, is available in the accompanying article in this issue and in the systematic evidence review on this topic, available through the USPSTF Web site (www.preventiveservices.ahrq.gov) and the National Guideline Clearinghouse (www.guideline.gov). The complete USPSTF recommendation statement (which includes a brief review of the supporting evidence) and the summary of the evidence are also available in print through the Agency for Healthcare Research and Quality Publications Clearinghouse (telephone, 800-358-9295; e-mail, ahrqpubs@ahrq.gov). *For a list of the members of the U.S. Preventive Services Task Force, see the Appendix.